Walvax | Briefing, News, Analysis, Research, Data

Walvax

Yunnan Watson Biotechnology Co., Ltd. is a modern biopharmaceutical company specializing in the research and manufacture

Yunnan Watson Biotechnology Co., Ltd. is a modern biopharmaceutical company specializing in the research and manufacture The company was listed on the GEM Board of China Shenzhen Stock Exchange in November 2010 (stock abbreviation: Watson Bio; stock code: 300142).

Sector

Healthcare

Industry

Biotech/Pharma

Sub-industry

Founded

Jan 16, 2001

HQ location

Yunnan, China

Legal name

Walvax Biotechnology Co., Ltd.

Website

http://www.walvax.com/

ir@walvax.com

Employees

1001-5000

All
News
Analysis
Research

Briefing May 17, 2022 03:10 PM · Consumer Staples | Consumer Discretionary

SARFT Launches Online drama distribution license

Briefing Apr 19, 2022 09:44 AM · Consumer Staples | Healthcare | Real Estate

The logistics sector opened lower, and Changlian shares fell by the limit

In-depth

Healthcare

Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis

‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’

Yesterday 02:13 PM

Briefing Feb 14, 2022 05:00 PM · Technology | Communication | Healthcare

Optical cable: it is proposed to set up Jiangsu Tong Optoelectronics Technology, which is mainly engaged in raw material trade

Briefing Jan 28, 2022 10:19 PM · Consumer Staples | Healthcare

Watson biology: the net profit in 2021 is expected to decrease by 54% - 64% year-on-year

Research

Healthcare

Digital Therapeutics - Revolution of the healthcare system

Nov 16, 2022 05:19 PM

Research

Healthcare

2022 China AI Health 30 Report

Nov 07, 2022 04:27 PM

Research

Healthcare

2022 China’s Healthcare Industry: An Introductory Handbook

Aug 29, 2022 05:45 PM

Research

Technology, Healthcare, Financials

WIA2020 | 30 Tech Entrepreneurs in China

Apr 22, 2021 03:11 PM

Briefing Jan 28, 2022 08:49 PM · Technology | Healthcare

Watson biology: 13 valent pneumococcal polysaccharide conjugate vaccine has been licensed in Morocco

Briefing Jan 10, 2022 09:19 AM · Technology | Healthcare | Financials

22 stocks were significantly large-scale, * ST Daji 5-day volume ratio reached 127 times

Briefing Dec 29, 2021 09:39 AM · Consumer Staples | Healthcare

The pharmaceutical and biological sector has been heavily sold off by the main funds in the past three days

Briefing Dec 28, 2021 06:49 PM · Technology | Consumer Staples | Healthcare

Huarong Holdings: terminate the purchase of 100% equity of Xinchao biology and resume trading tomorrow

Healthcare

Biopharma Company IASO Bio Nets Nearly CNY 500 Mn in Series C1

The Chinese leading cell therapy company IASO Bio will soon launch its first commercialized CAR-T product

Jan 18, 2023 10:43 AM

Insight

Healthcare

Opportunities and Challenges Hidden in the CGT Industry in China

CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.

Jan 17, 2023 05:48 PM

Briefing Dec 12, 2021 05:48 PM · Healthcare

Watson biology: Yuxi Watson plans to invest in the production and capacity expansion project of polysaccharide conjugate vaccine, with a total investment of 695 million yuan

Briefing Dec 10, 2021 08:19 PM · Technology | Healthcare | Automotive

Chongqing Road and Bridge: the shareholder Shanghai Linjun plans to increase its shareholding by 1% to 7%

Briefing Nov 10, 2021 01:38 PM · Technology | Healthcare

Shandong's largest hydrogen fuel cell hydrogen supply project completed

Insight

Healthcare

CAR-T Therapy Market Map in China

The market for cell therapy products such as CAR-T is expected to expand rapidly based on increasing investment from the industry and the implementation of advanced technologies.

Jan 16, 2023 02:39 PM

Healthcare

JHM Biopharma Raised Over CNY 100 Mn in Series A+

JHM Biopharma nets another CNY 100 Mn in its Series A round only 3 months after its A1 financing

Jan 16, 2023 09:57 AM

Briefing Sep 02, 2021 02:06 PM · Healthcare

Medical stocks continued to decline in the afternoon, with dongfulong falling more than 15%

Briefing Sep 02, 2021 10:22 AM · Healthcare | Financials

The biological vaccine sector weakened, and Watson biology fell more than 6%

Briefing Aug 06, 2021 01:08 PM · Technology | Healthcare | Financials

Will Huawei's server business be packaged for sale? Huawei insiders: business is affected but will not give up

Briefing Jul 29, 2021 10:01 AM

Back to Hong Kong, Chinese concept stocks rose collectively, and Wanguo data rose 17.5%

EqualOcean Analysis